Assistant Professor, Proctor Foundation, UCSF School of Medicine
Ophthalmology
Dr. Bruce D. Gaynor, MD
|
|
Give Review
Bruce D. Gaynor is an expert in the field of Ophthalmology. He studied medicine at Albert Einstein College of Medicine. He received awards:"CMS Meaningful Use Stage 1 Certification" and "Fellow (FAAO)". Doctor Bruce D. Gaynor, MD is also published. He has 64 publications published. The lastest publication: "Recurrent hypotension immediately after seizures in nortriptyline overdose.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- The Effect of Mass Azithromycin Distribution on Childhood Mortality: Beliefs and Estimates of Efficacy.
- Evidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments.
- Does mass azithromycin distribution impact child growth and nutrition in niger? A cluster-randomized trial.
- Importance of Including Borderline Cases in Trachoma Grader Certification.
- Reliability of trachoma clinical grading-assessing grading of marginal cases.
- Impact of Mass Azithromycin Distribution on Malaria Parasitemia during the Low-Transmission Season in Niger: A Cluster-Randomized Trial.
- Follicle size in trachoma: assessment of a well-known trachoma grading diagram.
- The Association between Latrine Use and Trachoma: A Secondary Cohort Analysis from a Randomized Clinical Trial.
- The Easiest Children to Reach Are Most Likely to Be Infected with Ocular Chlamydia trachomatis in Trachoma Endemic Areas of Niger.
- A Cluster-Randomized Controlled Trial Evaluating the Effects of Mass Azithromycin Treatment on Growth and Nutrition in Niger.
- Application of smartphone cameras for detecting clinically active trachoma.
- Trachoma: an update on prevention, diagnosis, and treatment.
- Gender and conjunctival bacterial infection in cicatricial trachoma.
- Diagnostic test characteristics of tests for ocular chlamydia after mass azithromycin distributions.
- Ribosomal RNA Evidence of Ocular Chlamydia trachomatis Infection Following 3 Annual Mass Azithromycin Distributions in Communities With Highly Prevalent Trachoma.
- Risk factors for ocular Chlamydia after three mass azithromycin distributions.
- Practice Patterns and Opinions in the Treatment of Acanthamoeba Keratitis.
- Latrine promotion for trachoma: assessment of mortality from a cluster-randomized trial in Ethiopia.
- Adverse events after mass azithromycin treatments for trachoma in ethiopia.
- How reliable are tests for trachoma? A latent class approach.
- Efficacy of latrine promotion on emergence of infection with ocular Chlamydia trachomatis after mass antibiotic treatment: a cluster-randomized trial.
- Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
- Slow resolution of clinically active trachoma following successful mass antibiotic treatments.
- Childhood mortality in a cohort treated with mass azithromycin for trachoma.
- The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma.
- Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma.
- Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial.
- Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.
- Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.
- Reduction and return of infectious trachoma in severely affected communities in Ethiopia.
- Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution.
- Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma.
- Complete elimination is a difficult goal for trachoma programs in severely affected communities.
- Chlamydia on children and flies after mass antibiotic treatment for trachoma.
- World blindness: the problem with prevalence.
- Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma.
- Mass antibiotic treatment and community protection in trachoma control programs.
- Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments.
- Eliminating trachoma in areas with limited disease.
- Rationale for mass antibiotic distribution for trachoma elimination.
- A rationale for continuing mass antibiotic distributions for trachoma.
- Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.
- Travel and implications for the elimination of trachoma in ethiopia.
- Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial.
- Comparison of an rRNA-based and DNA-based nucleic acid amplification test for the detection of Chlamydia trachomatis in trachoma.
- Topical ocular antibiotics induce bacterial resistance at extraocular sites.
- Microbiological cure times in acanthamoeba keratitis.
- Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year.
- Value of serum tricyclic antidepressant levels with massive nortriptyline overdose and persistent hypotension.
- Advances in diagnosis and management of herpetic uveitis.
- Presumed activation of herpetic keratouveitis after Argon laser peripheral iridotomy.
- Herpes simplex virus type 1 associated acute retinal necrosis following encephalitis.
- Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal.
- How reliable is the clinical exam in detecting ocular chlamydial infection?
- Recurrent hypotension immediately after seizures in nortriptyline overdose.
- What more is there to learn about trachoma?
- The real challenge: can we discover why trachoma is disappearing before it's gone?
- Pesky trachoma suspect finally caught.
- Single-dose azithromycin for trachoma.
- Trachoma decline and widespread use of antimicrobial drugs.
- Disappearance of trachoma from Western Nepal.
- A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
- Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of experts.
Schools
Rosalind Franklin University of Medicine and Science Chicago Medical School
Albert Einstein College Med
Lenox Hill HospNyu
Procedures Preformed
- Cataract Removal Surgery
Conditions Treated
- Blepharitis
- Cataract
- Glaucoma
- Senile Cataracts
- View All
Doctors Specialties
- Internal Medicine
- Ophthalmology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FAAO)
Education
-
Lenox Hill Hospital -
Albert Einstein College of Medicine -
Rosalind Franklin University of Medicine and Science
Drug Facts
| NPI NUMBER | 1972534253 | |
| NPPES Provider LastName | GAYNOR | |
| NPPES Provider FirstName | BRUCE | |
| NPPES Provider ZIPCode | 954057867 | |
| NPPES Provider State | CA | |
| Specialty Description | Ophthalmology | |
| Total Claim Count | 13.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1972534253 |
| Last Name Of The Provider | GAYNOR |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
|
Dr. Nannette L. Meyers, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen M. Rich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Landis A. Coghlan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John F. Trowbridge, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zuo-Fen Hauf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul A. Johnson, MD |
|
|
Dr. Aynna M. Yee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Danny H. Vo, MD |
|
|
Dr. Denise L. Kayser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas K. Schlesinger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brien A. Seeley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David E. Ulmer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark E. Jacobson, MD |
|
|
Dr. David Lightfoot, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dan R. Lightfoot, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie M. Perry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen A. Meffert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emil Shieh, MD
This Doctor is OpenDoctor Recommended.
|